REGENXBIO stock edges lower as short interest stays elevated

Published on 09/20/2026 at 10:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

REGENXBIO stock recently closed at USD 8.03 on Nasdaq on September 18, 2026, with about 13.24 percent of its float sold short as of August 31, 2026. The biotech’s latest quarterly figures and guidance frame the risk-reward for investors.

RGNX, US75901B1052, Illustration mit AI erstellt.

REGENXBIO Inc. stock (ISIN US75901B1052) last closed at USD 8.03 on Nasdaq on September 18, 2026, down about 2.6 percent for that trading day, while extended trading later showed a modest rebound to USD 8.16.

Short interest adds pressure to REGENXBIO stock

According to MarketBeat as of August 31, 2026, traders had sold about 7.50 million REGENXBIO shares short, corresponding to roughly 13.24 percent of the public float.

The same short interest overview from MarketBeat reports a short interest ratio of 4.9 days to cover, based on average daily trading volume, which indicates that it would take nearly five trading days for short sellers to cover their positions at typical liquidity levels.

REGENXBIO fundamentals and recent performance

Recent coverage of the stock on Nasdaq-linked portals shows REGENXBIO at USD 8.03 on September 18, 2026, and highlights that this level is within a 52-week trading range between USD 5.52 and USD 16.02, implying that the shares currently trade closer to the lower end of their one-year span than to the high, which underlines the cautious sentiment in the market.

Based on the same Reuters valuation overview for the RGNX listing, the intraday range on the latest trading day ran between USD 8.01 and USD 8.31, a relatively narrow band that still left the stock about 49.9 percent below its 52-week high of USD 16.02 and 45.5 percent above its 52-week low of USD 5.52.

Stock price level and investor perspective

At a closing price of USD 8.03 on Nasdaq on September 18, 2026, REGENXBIO stock trades well below the midpoint of its 52-week range between USD 5.52 and USD 16.02, a level that investors will weigh against the company’s gene therapy pipeline, cash position and upcoming data or regulatory catalysts.